Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
10.8
USD
|
+1.89%
|
|
+2.27%
|
-1.37%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,185
|
1,642
|
694.8
|
391.8
|
388.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,185
|
1,642
|
694.8
|
391.8
|
388.4
|
388.4
|
388.4
|
P/E ratio
|
-11.7
x
|
8.2
x
|
7.63
x
|
-3.48
x
|
-2.42
x
|
-1.75
x
|
-2.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
4.76
x
|
2.6
x
|
31.1
x
|
123
x
|
47.8
x
|
3.35
x
|
EV / Revenue
|
-
|
4.76
x
|
2.6
x
|
31.1
x
|
123
x
|
47.8
x
|
3.35
x
|
EV / EBITDA
|
-26,511,883
x
|
6,689,718
x
|
5,465,291
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-46.4
x
|
3.21
x
|
-
|
-3.67
x
|
-3.56
x
|
-3.6
x
|
-
|
FCF Yield
|
-2.15%
|
31.2%
|
-
|
-27.2%
|
-28.1%
|
-27.8%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,045
|
35,274
|
35,575
|
35,785
|
35,966
|
-
|
-
|
Reference price
2 |
33.82
|
46.56
|
19.53
|
10.95
|
10.80
|
10.80
|
10.80
|
Announcement Date
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
344.8
|
267.6
|
12.6
|
3.149
|
8.121
|
116.1
|
EBITDA
|
-
|
-44.7
|
245.5
|
127.1
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.05
|
-45.24
|
244.9
|
126.3
|
-151.1
|
-194.7
|
-252.3
|
-276.7
|
Operating Margin
|
-
|
-
|
71.03%
|
47.2%
|
-1,199.69%
|
-6,182.09%
|
-3,106.18%
|
-238.38%
|
Earnings before Tax (EBT)
1 |
-
|
-38.09
|
256.5
|
148.7
|
-109
|
-163.9
|
-221.2
|
-249.4
|
Net income
1 |
-22.45
|
-43.4
|
214.5
|
96.65
|
-112.6
|
-163.8
|
-237.9
|
-166.9
|
Net margin
|
-
|
-
|
62.22%
|
36.11%
|
-894.34%
|
-5,200.53%
|
-2,929.96%
|
-143.77%
|
EPS
2 |
-
|
-2.880
|
5.680
|
2.560
|
-3.150
|
-4.467
|
-6.188
|
-3.758
|
Free Cash Flow
1 |
-
|
-25.53
|
512
|
-
|
-106.7
|
-109
|
-108
|
-
|
FCF margin
|
-
|
-
|
148.49%
|
-
|
-847.34%
|
-3,461.69%
|
-1,329.89%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
208.53%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
238.65%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/22/20
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
104.3
|
240.5
|
152.5
|
41.72
|
19.49
|
53.9
|
12.6
|
-
|
-
|
-
|
-
|
1.5
|
1.5
|
-
|
-
|
EBITDA
|
79.58
|
213.7
|
-
|
3.53
|
-15
|
17.61
|
-24.71
|
-42.4
|
-43.06
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
79.41
|
213.5
|
120.8
|
3.335
|
-15.2
|
17.38
|
-24.93
|
-42.62
|
-43.28
|
-40.15
|
-44.31
|
-45.59
|
-49.23
|
-55.34
|
-64.84
|
Operating Margin
|
76.16%
|
88.78%
|
79.21%
|
7.99%
|
-78.03%
|
32.25%
|
-197.94%
|
-
|
-
|
-
|
-
|
-3,039.53%
|
-3,281.98%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
72.41
|
224
|
119.5
|
8.443
|
-1.986
|
22.75
|
-14.35
|
-33.07
|
-33.42
|
-28.19
|
-36.76
|
-38.06
|
-41.38
|
-47.68
|
-54.98
|
Net income
1 |
69.64
|
184.9
|
69.58
|
5.626
|
0.991
|
20.45
|
-15.55
|
-34.3
|
-32.24
|
-30.55
|
-36.76
|
-38.06
|
-41.38
|
-47.68
|
-54.98
|
Net margin
|
66.79%
|
76.87%
|
45.62%
|
13.49%
|
5.09%
|
37.94%
|
-123.47%
|
-
|
-
|
-
|
-
|
-2,537.07%
|
-2,758.58%
|
-
|
-
|
EPS
2 |
1.860
|
4.890
|
1.820
|
0.1500
|
0.0300
|
0.5500
|
-0.4400
|
-0.9600
|
-0.9000
|
-0.8500
|
-1.019
|
-1.037
|
-1.126
|
-1.286
|
-1.595
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/23/22
|
5/12/22
|
8/10/22
|
11/10/22
|
3/15/23
|
5/10/23
|
8/8/23
|
11/7/23
|
3/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-25.5
|
512
|
-
|
-107
|
-109
|
-108
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-30.2%
|
49%
|
15.9%
|
-18.2%
|
-25.3%
|
-28.8%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-23.1%
|
34.9%
|
11.8%
|
-15.8%
|
-21.7%
|
-24.5%
|
-
|
Assets
1 |
-
|
187.6
|
614.6
|
819.8
|
711.3
|
754.2
|
973
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
2.97
|
1
|
1
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
23.55%
|
31.76%
|
12.31%
|
-
|
Announcement Date
|
5/22/20
|
3/24/21
|
3/23/22
|
3/15/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
10.8
USD Average target price
34.4
USD Spread / Average Target +218.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.37% | 388M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|